Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) and Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.
Analyst Ratings
This is a summary of current ratings and price targets for Syndax Pharmaceuticals and Cartesian Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Syndax Pharmaceuticals | 1 | 0 | 10 | 0 | 2.82 |
| Cartesian Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
Syndax Pharmaceuticals currently has a consensus target price of $41.80, indicating a potential upside of 146.17%. Cartesian Therapeutics has a consensus target price of $32.60, indicating a potential upside of 360.52%. Given Cartesian Therapeutics’ higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than Syndax Pharmaceuticals.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Syndax Pharmaceuticals | $172.35 million | 8.73 | -$285.42 million | ($2.51) | -6.76 |
| Cartesian Therapeutics | $1.48 million | 145.01 | -$130.30 million | ($5.94) | -1.19 |
Cartesian Therapeutics has lower revenue, but higher earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Syndax Pharmaceuticals and Cartesian Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Syndax Pharmaceuticals | -87.52% | -372.94% | -39.11% |
| Cartesian Therapeutics | -8,550.65% | N/A | -29.84% |
Risk and Volatility
Syndax Pharmaceuticals has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.
Institutional & Insider Ownership
86.9% of Cartesian Therapeutics shares are held by institutional investors. 4.8% of Syndax Pharmaceuticals shares are held by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Cartesian Therapeutics beats Syndax Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
About Cartesian Therapeutics
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
